Abstract
Neurodegenerative diseases (NDD) are incurable and the most prevalent cognitive and motor disorders of elderly. Mitochondria are essential for a wide range of cellular processes playing a pivotal role in a number of cellular functions like metabolism, intracellular signaling, apoptosis, and immunity. A plethora of evidence indicates the central role of mitochondrial functions in pathogenesis of many aging related NDD. Considering how mitochondria function in neurodegenerative diseases, oxidative stress, and mutations in mtDNA both contribute to aging. Many substantial reports suggested the involvement of numerous contributing factors including, mitochondrial dysfunction, oxidative stress, mitophagy, accumulation of somatic mtDNA mutations, compromised mitochondrial dynamics, and transport within axons in neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and Amyotrophic Lateral Sclerosis. Therapies therefore target fundamental mitochondrial processes such as energy metabolism, free-radical generation, mitochondrial biogenesis, mitochondrial redox state, mitochondrial dynamics, mitochondrial protein synthesis, mitochondrial quality control, and metabolism hold great promise to develop pharmacological based therapies in NDD. By emphasizing the most efficient pharmacological strategies to target dysfunction of mitochondria in the treatment of neurodegenerative diseases, this review serves the scientific community engaged in translational medical science by focusing on the establishment of novel, mitochondria-targeted treatment strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of Data and Materials
Not applicable.
Code Availability
Not applicable.
References
Agnihotri A, Aruoma OI (2019) Alzheimer’s disease and Parkinson’s disease: a nutritional toxicology perspective of the impact of oxidative stress, mitochondrial dysfunction, nutrigenomics and environmental chemicals. J Am Coll Nutr 39:16–27. https://doi.org/10.1080/07315724.2019.1683379
Akbar M, Essa MM, Daradkeh G, Abdelmegeed MA, Choi Y, Mahmood L, Song BJ (2016) Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress. Brain Res 1637:34–55. https://doi.org/10.1016/j.brainres.2016.02.016
Aliev G, Seyidova D, Lamb BT, Obrenovich ME, Siedlak SL, Vinters HV, Friedland RP, LaManna JC, Smith MA, Perry G (2003) Mitochondria and vascular lesions as a central target for the development of Alzheimer’s disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res 25:665–674. https://doi.org/10.1179/016164103101201977
Allen SP, Hall B, Woof R, Francis L, Gatto N, Shaw AC, Myszczynska M, Hemingway J, Coldicott I, Willcock A, Job L, Hughes RM, Boschian C, Bayatti N, Heath PR, Bandmann O, Mortiboys H, Ferraiuolo L, Shaw PJ (2019) C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain 142:3771–3790. https://doi.org/10.1093/BRAIN/AWZ302
Altanbyek V, Cha SJ, Kang GU, Im DS, Lee S, Kim HJ, Kim K (2016) Imbalance of mitochondrial dynamics in Drosophila models of amyotrophic lateral sclerosis. Biochem Biophys Res Commun 481:259–264. https://doi.org/10.1016/J.BBRC.2016.10.134
Amor S, Puentes F, Baker D, Van Der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology. Wiley Online Libr 129:154–169. https://doi.org/10.1111/j.1365-2567.2009.03225.x
Andersen JK (2004) Oxidative stress in neurodegeneration: cause or consequence? Nat Med 107(10):S18–S25. https://doi.org/10.1038/nrn1434
Andrews ZB, Diano S, Horvath TL (2005) Mitochondrial uncoupling proteins in the cns: in support of function and survival. Nat Rev Neurosci 611(6):829–840. https://doi.org/10.1038/nrn1767
Anzell AR, Maizy R, Przyklenk K, Sanderson TH (2017) Mitochondrial quality control and disease: insights into ischemia-reperfusion injury. Mol Neurobiol 553(55):2547–2564. https://doi.org/10.1007/S12035-017-0503-9
Apel K, Hirt H (2004) Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol. https://doi.org/10.1146/annurev.arplant.55.031903.141701
Area-Gomez E, Guardia-Laguarta C, Schon EA, Przedborski S (2019) Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas. J Clin Invest 129:34–45. https://doi.org/10.1172/JCI120848
Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell. https://doi.org/10.1016/j.cell.2005.02.001
Banoth B, Cassel SL (2018) Mitochondria in innate immune signaling. Transl Res 202:52–68. https://doi.org/10.1016/j.trsl.2018.07.014.Mitochondria
Bélanger M, Allaman I, Magistretti PJ (2011) Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 14:724–738. https://doi.org/10.1016/j.cmet.2011.08.016
Blanchet J, Longpré F, Bureau G, Morissette M, DiPaolo T, Bronchti G, Martinoli MG (2008) Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog Neuro-Psychopharmacology Biol Psychiatry 32:1243–1250. https://doi.org/10.1016/J.PNPBP.2008.03.024
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson’s disease. Front Neuroanat. https://doi.org/10.3389/fnana.2015.00091
Bo H, Kang W, Jiang N, Wang X, Zhang Y, Ji LL (2014) Exercise-induced neuroprotection of hippocampus in APP/PS1 transgenic mice via upregulation of mitochondrial 8-oxoguanine DNA glycosylase. Oxid Med Cell Longev. https://doi.org/10.1155/2014/834502
Bordt EA, Clerc P, Roelofs BA, Saladino AJ, Tretter L, Adam-Vizi V, Cherok E, Khalil A, Yadava N, Ge SX, Francis TC, Kennedy NW, Picton LK, Kumar T, Uppuluri S, Miller AM, Itoh K, Karbowski M, Sesaki H, Hill RB, Polster BM (2017) The putative Drp1 inhibitor mdivi-1 Is a reversible mitochondrial complex I inhibitor that modulates reactive oxygen species. Dev Cell 40:583-594.e6. https://doi.org/10.1016/J.DEVCEL.2017.02.020
Burman JL, Pickles S, Wang C, Sekine S, Vargas JNS, Zhang Z, Youle AM, Nezich CL, Wu X, Hammer JA, Youle RJ (2017) Mitochondrial fission facilitates the selective mitophagy of protein aggregates. J Cell Biol 216:3231–3247. https://doi.org/10.1083/JCB.201612106
Burtscher J, Burtscher M, Millet GP (2021) The central role of mitochondrial fitness on antiviral defenses: an advocacy for physical activity during the COVID-19 pandemic. Redox Biol. 43:101976. https://doi.org/10.1016/J.REDOX.2021.101976
Reitz C (2012) Alzheimer’s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimers Dis. https://doi.org/10.1155/2012/369808
Cadenas E, Davies KJA (2000) Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med. https://doi.org/10.1016/S0891-5849(00)00317-8
Cai Q, Tammineni P (2016) Alterations in mitochondrial quality control in alzheimer’s disease. Front Cell Neurosci. https://doi.org/10.3389/fncel.2016.00024
Calì T, Ottolini D, Brini M (2012) Mitochondrial Ca2+ and neurodegeneration. Cell Calcium 52:73–85. https://doi.org/10.1016/J.CECA.2012.04.015
Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Genet 20:4515–4529. https://doi.org/10.1093/HMG/DDR381
Campbell S, MacQueen G (2006) An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry. https://doi.org/10.1097/01.yco.0000194371.47685.f2
Cantó C, Auwerx J (2009) Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab 20:325–331. https://doi.org/10.1016/J.TEM.2009.03.008
Canugovi C, Shamanna RA, Croteau DL, Bohr VA (2014) Base excision DNA repair levels in mitochondrial lysates of Alzheimer’s disease. Neurobiol Aging 35:1293–1300. https://doi.org/10.1016/j.neurobiolaging.2014.01.004
Cardoso SM, Proença MT, Santos S, Santana I, Oliveira CR (2004) Cytochrome c oxidase is decreased in Alzheimer’s disease platelets. Neurobiol Aging 25:105–110. https://doi.org/10.1016/S0197-4580(03)00033-2
Cenini G, Lloret A, Cascella R (2019) Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view. Oxid Med Cell Longev. https://doi.org/10.1155/2019/2105607
Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon EA, Dantzer F, Auwerx J, Viscomi C, Zeviani M (2014) NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 19:1042–1049. https://doi.org/10.1016/j.cmet.2014.04.001
Cha MY, Kim DK, Mook-Jung I (2015) The role of mitochondrial DNA mutation on neurodegenerative diseases. Exp Mol Med 47:e150. https://doi.org/10.1038/emm.2014.122
Chakravorty A, Jetto CT, Manjithaya R (2019) Dysfunctional mitochondria and mitophagy as drivers of Alzheimer’s disease pathogenesis. Front Aging Neurosci
Chang CY, Liang MZ, Chen L (2019) Current progress of mitochondrial transplantation that promotes neuronal regeneration. Transl Neurodegener 8:1–12. https://doi.org/10.1186/S40035-019-0158-8/FIGURES/2
Chang X, Zhang W, Zhao Z, Ma C, Zhang T, Meng Q, Yan P, Zhang L, Zhao Y (2020) Regulation of mitochondrial quality control by natural drugs in the treatment of cardiovascular diseases: potential and advantages. Front Cell Dev Biol. 8:616139. https://doi.org/10.3389/fcell.2020.616139
Che HVB, Metzger S, Portal E, Deyle C, Riess O, Nguyen HP (2011) Localization of sequence variations in PGC-1 influence their modifying effect in Huntington disease. Mol Neurodegener 6:1–7. https://doi.org/10.1186/1750-1326-6-1/TABLES/6
Chen C-M (2011) Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington’s disease. Chang Gung Med J 34:135–152
Chen H, Chan DC (2009) Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet. https://doi.org/10.1093/hmg/ddp326
Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160:189–200. https://doi.org/10.1083/JCB.200211046/VIDEO-3
Chen W, Hu Y, Ju D (2020) Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B 10:1347–1359. https://doi.org/10.1016/J.APSB.2020.01.015
Chen X, Guo C, Kong J (2012) Oxidative stress in neurodegenerative diseases. Neural Regen Res 7:376–385. https://doi.org/10.3969/j.issn.1673-5374.2012.05.009
Cheng H, Shang Y, Jiang L, Shi TL, Wang L (2015) The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer’s disease: a meta-analysis. Int J Neurosci 126:299–307. https://doi.org/10.3109/00207454.2015.1015722
Choo YS, Johnson GVW, MacDonald M, Detloff PJ, Lesort M (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 13:1407–1420. https://doi.org/10.1093/hmg/ddh162
Ciccone S, Maiani E, Bellusci G, Diederich M, Gonfloni S (2013) Parkinson’s disease: a complex interplay of mitochondrial DNA alterations and oxidative stress. Int J Mol Sci 14:2388–2409. https://doi.org/10.3390/ijms14022388
Ciron C, Lengacher S, Dusonchet J, Aebischer P, Schneider BL (2012) Sustained expression of PGC-1α in the rat nigrostriatal system selectively impairs dopaminergic function. Hum Mol Genet 21:1861–1876. https://doi.org/10.1093/HMG/DDR618
Clark J, Reddy S, Zheng K, Betensky RA, Simon DK (2011) Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson’s disease. BMC Med Genet 12:1–9. https://doi.org/10.1186/1471-2350-12-69/TABLES/2
Cobley JN, Fiorello ML, Bailey DM (2018) 13 reasons why the brain is susceptible to oxidative stress. Redox Biol 15:490–503. https://doi.org/10.1016/j.redox.2018.01.008
Criscuolo D, Avolio R, Matassa DS, Esposito F (2021) Targeting mitochondrial protein expression as a future approach for cancer therapy. Front. Oncol. 11:797265. https://doi.org/10.3389/fonc.2021.797265
Cunha-Oliveira T, Montezinho L, Mendes C, Firuzi O, Saso L, Oliveira PJ, Silva FSG (2020) Oxidative stress in amyotrophic lateral sclerosis: pathophysiology and opportunities for pharmacological intervention. Oxid Med Cell Longev. https://doi.org/10.1155/2020/5021694
Cunha-Santos J, Duarte-Neves J, Carmona V, Guarente L, De Almeida LP, Cavadas C (2016) Caloric restriction blocks neuropathology and motor deficits in Machado-Joseph disease mouse models through SIRT1 pathway. Nat Commun 71(7):1–14. https://doi.org/10.1038/ncomms11445
Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave KA, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ (2020) Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov 199(19):609–633. https://doi.org/10.1038/s41573-020-0072-x
Delic V, Kurien C, Cruz J, Zivkovic S, Barretta J, Thomson A, Hennessey D, Joseph J, Ehrhart J, Willing AE, Bradshaw P, Garbuzova-Davis S (2018) Discrete mitochondrial aberrations in the spinal cord of sporadic ALS patients. J Neurosci Res 96:1353–1366. https://doi.org/10.1002/JNR.24249
Dematteis G, Vydmantaitė G, Ruffinatti FA, Chahin M, Farruggio S, Barberis E, Ferrari E, Marengo E, Distasi C, Morkūnienė R, Genazzani AA, Grilli M, Grossini E, Corazzari M, Manfredi M, Lim D, Jekabsone A, Tapella L (2020) Proteomic analysis links alterations of bioenergetics, mitochondria-ER interactions and proteostasis in hippocampal astrocytes from 3xTg-AD mice. Cell Death Dis 118(11):1–16. https://doi.org/10.1038/s41419-020-02911-1
Dominy JE, Puigserver P (2013) Mitochondrial biogenesis through activation of nuclear signaling proteins. Cold Spring Harb Perspect Biol 5:a015008. https://doi.org/10.1101/CSHPERSPECT.A015008
DuBoff B, Götz J, Feany MB (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 75:618–632. https://doi.org/10.1016/J.NEURON.2012.06.026
Elfawy HA, Das B (2019) Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: etiologies and therapeutic strategies. Life Sci 218:165–184. https://doi.org/10.1016/J.LFS.2018.12.029
Erustes AG, D’Eletto M, Guarache GC, Ureshino RP, Bincoletto C, da Silva Pereira GJ, Piacentini M, Smaili SS (2021) Overexpression of α-synuclein inhibits mitochondrial Ca2+ trafficking between the endoplasmic reticulum and mitochondria through MAMs by altering the GRP75–IP3R interaction. J Neurosci Res 99:2932–2947. https://doi.org/10.1002/JNR.24952
Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E (2012) Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322:254–262. https://doi.org/10.1016/J.JNS.2012.05.030
Feng ST, Wang ZZ, Yuan YH, Sun HM, Chen NH, Zhang Y (2021a) Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: implications for Parkinson’s disease. Eur J Neurosci 53:2946–2959. https://doi.org/10.1111/EJN.14699
Feng ST, Wang ZZ, Yuan YH, Sun HM, Chen NH, Zhang Y (2019) Mangiferin: a multipotent natural product preventing neurodegeneration in Alzheimer’s and Parkinson’s disease models. Pharmacol Res 146:104336. https://doi.org/10.1016/J.PHRS.2019.104336
Feng ST, Wang ZZ, Yuan YH, Wang X. Le, Guo ZY, Hu JH, Yan X, Chen NH, Zhang Y (2021b) Inhibition of dynamin-related protein 1 ameliorates the mitochondrial ultrastructure via PINK1 and Parkin in the mice model of Parkinson’s disease. Eur J Pharmacol 907. https://doi.org/10.1016/J.EJPHAR.2021.174262
Feng ST, Wang ZZ, Yuan YH, Wang X. Le, Sun HM, Chen NH, Zhang Y (2020) Dynamin-related protein 1: a protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson’s disease. Pharmacol Res 151:104553. https://doi.org/10.1016/j.phrs.2019.104553
Frank M, Duvezin-Caubet S, Koob S, Occhipinti A, Jagasia R, Petcherski A, Ruonala MO, Priault M, Salin B, Reichert AS (2012) Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner. Biochim Biophys Acta - Mol Cell Res 1823:2297–2310. https://doi.org/10.1016/J.BBAMCR.2012.08.007
Frederiksen KS, Gjerum L, Waldemar G, Hasselbalch SG (2018) Effects of physical exercise on Alzheimer’s disease biomarkers: a systematic review of intervention studies. J Alzheimer’s Dis 61:359–372. https://doi.org/10.3233/JAD-170567
Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798–4811. https://doi.org/10.1038/sj.onc.1209608
Gan X, Huang S, Wu L, Wang Y, Hu G, Li G, Zhang H, Yu H, Swerdlow RH, Chen JX, Yan SS (2014) Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer’s disease cybrid cell. Biochim Biophys Acta - Mol Basis Dis 1842:220–231. https://doi.org/10.1016/J.BBADIS.2013.11.009
Gandhi S, Abramov AY (2012) Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev. https://doi.org/10.1155/2012/428010
Gao J, Wang L, Liu J, Xie F, Su B, Wang X (2017) Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases 6:25
Gatt AP, Duncan OF, Attems J, Francis PT, Ballard CG, Bateman JM (2016) Dementia in Parkinson’s disease is associated with enhanced mitochondrial complex I deficiency. Mov Disord 31:352–359. https://doi.org/10.1002/MDS.26513
Ghosh A, Tyson T, George S, Hildebrandt EN, Steiner JA, Madaj Z, Schulz E, Machiela E, McDonald WG, Escobar Galvis ML, Kordower JH, Van Raamsdonk JM, Colca JR, Brundin P (2016) Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson’s disease. Sci Transl Med 8. https://doi.org/10.1126/scitranslmed.aag2210
Gilmozzi V, Gentile G, Castelo Rueda MP, Hicks AA, Pramstaller PP, Zanon A, Lévesque M, Pichler I (2020) Interaction of alpha-synuclein with lipids: mitochondrial cardiolipin as a critical player in the pathogenesis of Parkinson’s disease. Front Neurosci 14:578993. https://doi.org/10.3389/fnins.2020.578993
Giorgi C, Agnoletto C, Bononi A, Bonora M, De Marchi E, Marchi S, Missiroli S, Patergnani S, Poletti F, Rimessi A, Suski JM, Wieckowski MR, Pinton P (2012) Mitochondrial calcium homeostasis as potential target for mitochondrial medicine. Mitochondrion 12:77–85. https://doi.org/10.1016/j.mito.2011.07.004
Gomes LC, Scorrano L (2008) High levels of Fis1, a pro-fission mitochondrial protein, trigger autophagy. Biochim Biophys Acta - Bioenerg 1777:860–866. https://doi.org/10.1016/J.BBABIO.2008.05.442
Goyal S, Chaturvedi RK (2020) Mitochondrial protein import dysfunction in pathogenesis of neurodegenerative diseases. Mol Neurobiol 584(58):1418–1437. https://doi.org/10.1007/S12035-020-02200-0
Gueguen N, Desquiret-Dumas V, Leman G, Chupin S, Baron S, Nivet-Antoine V, Vessières E, Ayer A, Henrion D, Lenaers G, Reynier P, Procaccio V (2015) Resveratrol directly binds to mitochondrial complex i and increases oxidative stress in brain mitochondria of aged mice. PLoS One 10:e0144290. https://doi.org/10.1371/JOURNAL.PONE.0144290
Guo L, Tian J, Du H (2017) Mitochondrial dysfunction and synaptic transmission failure in Alzheimer’s disease. J Alzheimers Dis 57:1071–1086. https://doi.org/10.3233/JAD-160702
Guo W, Stoklund Dittlau K, Van Den Bosch L (2020) Axonal transport defects and neurodegeneration: molecular mechanisms and therapeutic implications. Semin Cell Dev Biol 99:133–150. https://doi.org/10.1016/j.semcdb.2019.07.010
Guzy RD, Schumacker PT (2006) Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol. Blackwell Publishing Ltd, pp. 807–819. https://doi.org/10.1113/expphysiol.2006.033506
Hall CN, Klein-Flügge MC, Howarth C, Attwell D (2012) Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing. J Neurosci. https://doi.org/10.1523/JNEUROSCI.0026-12.2012
Heneka MT, Fink A, Doblhammer G (2015) Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 78:284–294. https://doi.org/10.1002/ANA.24439
Herst PM, Rowe MR, Carson GM, Berridge MV (2017) Functional mitochondria in health and disease. Front Endocrinol
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PLR, Jones PK, Petersen RB, Perry G, Smith MA (2001) Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci 21:3017–3023. https://doi.org/10.1523/JNEUROSCI.21-09-03017.2001
Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF (2010) Resveratrol protects against peripheral deficits in a mouse model of Huntington’s disease. Exp Neurol 225:74–84. https://doi.org/10.1016/J.EXPNEUROL.2010.05.006
Huang L-K, Chao S-P, Hu C-J (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27:18. https://doi.org/10.1186/s12929-019-0609-7
Hudry E, Vandenberghe LH (2019) Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101:839–862. https://doi.org/10.1016/J.NEURON.2019.02.017
Investigators NET (2015) Pioglitazone in early Parkinson’s disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol 14:795–803. https://doi.org/10.1016/S1474-4422(15)00144-1
Jaber SM, Ge SX, Milstein JL, VanRyzin JW, Waddell J, Polster BM (2020) Idebenone has distinct effects on mitochondrial respiration in cortical astrocytes compared to cortical neurons due to differential NQO1 activity. J Neurosci 40:4609–4619. https://doi.org/10.1523/JNEUROSCI.1632-17.2020
Jamwal S, Blackburn JK, Elsworth JD (2021) PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacol Ther 219:107705. https://doi.org/10.1016/j.pharmthera.2020.107705
Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC (2017) Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 7:a024240. https://doi.org/10.1101/cshperspect.a024240
Jones AWE, Yao Z, Vicencio JM, Karkucinska-Wieckowska A, Szabadkai G (2012) PGC-1 family coactivators and cell fate: roles in cancer, neurodegeneration, cardiovascular disease and retrograde mitochondria–nucleus signalling. Mitochondrion 12:86–99. https://doi.org/10.1016/J.MITO.2011.09.009
Kale MB, Bajaj K, Umare M, Wankhede NL, Taksande BG, Umekar MJ, Upaganlawar A (2021) Exercise and nutraceuticals: eminent approach for diabetic neuropathy. Curr Mol Pharmacol 14. https://doi.org/10.2174/1874467214666210629123010
Kandimalla R, Manczak M, Fry D, Suneetha Y, Sesaki H, Reddy PH (2016) Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Genet 25:4881–4897. https://doi.org/10.1093/hmg/ddw312
Kandimalla R, Reddy PH (2016) Multiple faces of dynamin-related protein 1 and its role in Alzheimer’s disease pathogenesis. Biochim Biophys Acta - Mol Basis Dis 1862:814–828. https://doi.org/10.1016/J.BBADIS.2015.12.018
Kawamata H, Manfredi G (2018) Correction: proteinopathies and OXPHOS dysfunction in neurodegenerative diseases. J Cell Biol 217:429. https://doi.org/10.1083/JCB.20170917212192017C
Khan A, Ali T, Rehman SU, Khan MS, Alam SI, Ikram M, Muhammad T, Saeed K, Badshah H, Kim MO (2018) Neuroprotective effect of quercetin against the detrimental effects of LPS in the adult mouse brain. Front Pharmacol 9:1383. https://doi.org/10.3389/fphar.2018.01383
Khraiwesh H, López-Domínguez JA, Fernández del Río L, Gutierrez-Casado E, López-Lluch G, Navas P, de Cabo R, Ramsey JJ, Burón MI, Villalba JM, González-Reyes JA (2014) Mitochondrial ultrastructure and markers of dynamics in hepatocytes from aged, calorie restricted mice fed with different dietary fats. Exp Gerontol 56:77–88. https://doi.org/10.1016/J.EXGER.2014.03.023
Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J 26:3169–3179. https://doi.org/10.1038/SJ.EMBOJ.7601758
Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Flint Beal M, Ferrante RJ (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet 19:3919–3935. https://doi.org/10.1093/HMG/DDQ306
Krishnan KJ, Ratnaike TE, De Gruyter HLM, Jaros E, Turnbull DM (2012) Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer’s disease. Neurobiol Aging 33:2210–2214. https://doi.org/10.1016/j.neurobiolaging.2011.08.009
Lautrup S, Sinclair DA, Mattson MP, Fang EF (2019) NAD(+) in brain aging and neurodegenerative disorders. Cell Metab 30:630–655. https://doi.org/10.1016/j.cmet.2019.09.001
Lee JS, Yoon YG, Yoo SH, Jeong NY, Jeong SH, Lee SY, Jung DI, Jeong SY, Yoo YH (2012) Histone deacetylase inhibitors induce mitochondrial elongation. J Cell Physiol 227:2856–2869. https://doi.org/10.1002/JCP.23027
Li J, Hart RP, Mallimo EM, Swerdel MR, Kusnecov AW, Herrup K (2013) EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia. Nat Neurosci 1612(16):1745–1753. https://doi.org/10.1038/nn.3564
Li T, Chen L, Yu Y, Yang B, Li P, Tan X-Q (2019) Resveratrol alleviates hypoxia/reoxygenation injury-induced mitochondrial oxidative stress in cardiomyocytes. Mol Med Rep 19:2774–2780. https://doi.org/10.3892/mmr.2019.9943
Li Z, Okamoto K-I, Hayashi Y, Sheng M (2004) The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119:873–887. https://doi.org/10.1016/j.cell.2004.11.003
Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jäger S, Vianna CR, Reznick RM, Cui L, Manieri M, Donovan MX, Wu Z, Cooper MP, Fan MC, Rohas LM, Zavacki AM, Cinti S, Shulman GI, Lowell BB, Krainc D, Spiegelman BM (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 119:121–135. https://doi.org/10.1016/J.CELL.2004.09.013
Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795. https://doi.org/10.1038/nature05292
Lin MY, Cheng XT, Xie Y, Cai Q, Sheng ZH (2017) Removing dysfunctional mitochondria from axons independent of mitophagy under pathophysiological conditions. Autophagy 13:1792–1794. https://doi.org/10.1080/15548627.2017.1356552
Linnane AW, Zhang C, Baumer A, Nagley P (1992) Mitochondrial DNA mutation and the ageing process: bioenergy and pharmacological intervention. Mutat Res Dnaging 275:195–208. https://doi.org/10.1016/0921-8734(92)90023-I
Liu H, You L, Wu J, Zhao M, Guo R, Zhang H, Su R, Mao Q, Deng D, Hao Y (2020) Berberine suppresses influenza virus-triggered NLRP3 inflammasome activation in macrophages by inducing mitophagy and decreasing mitochondrial ROS. J Leukoc Biol 108:253–266. https://doi.org/10.1002/jlb.3ma0320-358rr
Loncke J, Kaasik A, Bezprozvanny I, Parys JB, Kerkhofs M, Bultynck G (2021) Balancing ER-mitochondrial Ca2+ fluxes in health and disease. Trends Cell Biol 31:598–612. https://doi.org/10.1016/J.TCB.2021.02.003
Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D (2014) Neuroinflammation: the role and consequences. Neurosci Res. https://doi.org/10.1016/j.neures.2013.10.004
Ma K, Chen G, Li W, Kepp O, Zhu Y, Chen Q (2020) Mitophagy, mitochondrial homeostasis, and cell fate. Front Cell Dev Biol 8:467. https://doi.org/10.3389/fcell.2020.00467
Mallet D, Goutaudier R, Barbier EL, Carnicella S, Colca JR, Fauvelle F, Boulet S (2022) Re-routing metabolism by the mitochondrial pyruvate carrier inhibitor MSDC-0160 attenuates neurodegeneration in a rat model of Parkinson’s disease. Mol Neurobiol. https://doi.org/10.1101/2022.01.17.476616
Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy PH (2016) Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Genet 25:5148–5166. https://doi.org/10.1093/hmg/ddw330
Manczak M, Kandimalla R, Yin X, Hemachandra Reddy P (2019) Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity. Hum Mol Genet 28:177–199. https://doi.org/10.1093/HMG/DDY335
Manczak M, Reddy PH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet 21:2538–2547. https://doi.org/10.1093/HMG/DDS072
Manor U, Bartholomew S, Golani G, Christenson E, Kozlov M, Higgs H, Spudich J, Lippincott-Schwartz J (2015) A mitochondria-anchored isoform of the actin-nucleating spire protein regulates mitochondrial division. Elife 4:1–27. https://doi.org/10.7554/eLife.08828
Marde VS, Atkare UA, Gawali SV, Tiwari PL, Badole SP, Wankhede NL, Taksande BG, Upaganlawar AB, Umekar MJ, Kale MB (2022) Alzheimer’s disease and sleep disorders: insights into the possible disease connections and the potential therapeutic targets. Asian J Psychiatr 68. https://doi.org/10.1016/j.ajp.2021.102961
Marde VS, Tiwari PL, Wankhede NL, Taksande BG, Upaganlawar AB, Umekar MJ, Kale MB (2021) Neurodegenerative Disorders Associated with Genes of Mitochondria 7:1–8. https://doi.org/10.1186/S43094-021-00215-5
Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, Vitek J, Stacy M, Turner D, Verhagen L, Bakay R, Watts R, Guthrie B, Jankovic J, Simpson R, Tagliati M, Alterman R, Stern M, Baltuch G, Starr PA, Larson PS, Ostrem JL, Nutt J, Kieburtz K, Kordower JH, Olanow CW (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9:1164–1172. https://doi.org/10.1016/S1474-4422(10)70254-4
Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M, Di Castelnuovo A, Ciavardelli D, Silvestri E, Canzoniero LMT, Sekler I, Pandolfi A, Sensi SL (2012) Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis 3:e448–e448. https://doi.org/10.1038/cddis.2012.189
Melo TQ, Copray SJCVM, Ferrari MFR (2018) Alpha-synuclein toxicity on protein quality control, mitochondria and endoplasmic reticulum. Neurochem Res 4312(43):2212–2223. https://doi.org/10.1007/S11064-018-2673-X
Mergenthaler P, Lindauer U, Dienel GA, Meisel A (2013) Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36:587–597. https://doi.org/10.1016/j.tins.2013.07.001
Mishra P, Chan DC (2014) Mitochondrial dynamics and inheritance during cell division, development and disease. Nat Rev Mol Cell Biol 1510(15):634–646. https://doi.org/10.1038/nrm3877
Missiroli S, Genovese I, Perrone M, Vezzani B, Vitto VAM, Giorgi C (2020) The role of mitochondria in inflammation: from cancer to neurodegenerative disorders. J Clin Med 9:740. https://doi.org/10.3390/jcm9030740
Mitochondrial Ca Y, Moccia F, Zhang D, Wang F, Li P, Gao Y (2022) Mitochondrial Ca2+ homeostasis: emerging roles and clinical significance in cardiac remodeling. Int J. Mol Sci 23:3025. https://doi.org/10.3390/IJMS23063025
Morató L, Ruiz M, Boada J, Calingasan NY, Galino J, Guilera C, Jové M, Naudí A, Ferrer I, Pamplona R, Serrano M, Portero-Otín M, Beal MF, Fourcade S, Pujol A (2015) Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy. Cell Death Differ 22:1742–1753. https://doi.org/10.1038/cdd.2015.20
Moreira PI, Zhu X, Wang X, Lee H-G, Nunomura A, Petersen RB, Perry G, Smith MA (2010) Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 1802:212–220. https://doi.org/10.1016/j.bbadis.2009.10.007
Niu S, Zhang LK, Zhang L, Zhuang S, Zhan X, Chen WY, Du S, Yin L, You R, Li CH, Guan YQ (2017) Inhibition by multifunctional magnetic nanoparticles loaded with alpha-synuclein RNAi plasmid in a Parkinson’s disease model. Theranostics 7:344. https://doi.org/10.7150/THNO.16562
Nunnari J, Suomalainen A (2012) Mitochondria: in sickness and in health. Cell. https://doi.org/10.1016/j.cell.2012.02.035
Oliveira JMA (2010) Nature and cause of mitochondrial dysfunction in Huntington’s disease: focusing on huntingtin and the striatum. J Neurochem 114:1–12. https://doi.org/10.1111/J.1471-4159.2010.06741.X
Onyango IG, Lu J, Rodova M, Lezi E, Crafter AB, Swerdlow RH (2010) Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta - Mol Basis Dis. https://doi.org/10.1016/j.bbadis.2009.07.014
Orsucci D, Mancuso M, Ienco EC, LoGerfo A, Siciliano G (2011) Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Med Chem 18:4053–4064. https://doi.org/10.2174/092986711796957257
Palikaras K, Tavernarakis N (2012) Mitophagy in neurodegeneration and aging. Front Genet. https://doi.org/10.3389/fgene.2012.00297
Panchal K, Tiwari AK (2019) Mitochondrial dynamics, a key executioner in neurodegenerative diseases. Mitochondrion 47:151–173. https://doi.org/10.1016/J.MITO.2018.11.002
Paudel YN, Angelopoulou E, Piperi C, Shaikh MF, Othman I (2020) Emerging neuroprotective effect of metformin in Parkinson’s disease: a molecular crosstalk. Pharmacol Res. https://doi.org/10.1016/j.phrs.2019.104593
Peng K, Yang L, Wang J, Ye F, Dan G, Zhao Y, Cai Y, Cui Z, Ao L, Liu J, Zou Z, Sai Y, Cao J (2016) The interaction of mitochondrial biogenesis and fission/fusion mediated by PGC-1α regulates rotenone-induced dopaminergic neurotoxicity. Mol Neurobiol 545(54):3783–3797. https://doi.org/10.1007/S12035-016-9944-9
Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 98:1141–1148. https://doi.org/10.1111/J.1471-4159.2006.04018.X
Picca A, Calvani R, Coelho-Junior HJ, Marzetti E (2021) Cell death and inflammation: the role of mitochondria in health and disease. Cells 10:537. https://doi.org/10.3390/cells10030537
Quansah E, Peelaerts W, Langston JW, Simon DK, Colca J, Brundin P (2018) Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. Mol Neurodegener 13:28. https://doi.org/10.1186/s13024-018-0260-x
Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GVW (2008) Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells. J Biol Chem 283:25628–25637. https://doi.org/10.1074/jbc.m804291200
Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS, Mintzer J, Lerner A, Levey A, Burke J, Sano M, Turner S, Zamrini E, Grill J, Marson D (2018) Adeno-associated viral vector (Serotype 2)–nerve growth factor for patients with Alzheimer disease: a randomized clinical trial. JAMA Neurol 75:834–841. https://doi.org/10.1001/JAMANEUROL.2018.0233
Reddy PH (2009) Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer’s disease. CNS Spectr 14:8–13. https://doi.org/10.1017/S1092852900024901
Rey F, Ottolenghi S, Giallongo T, Balsari A, Martinelli C, Rey R, Allevi R, Giulio AMD, Zuccotti GV, Mazzucchelli S, Foresti R, Samaja M, Carelli S (2021) Mitochondrial Metabolism as target of the neuroprotective role of erythropoietin in Parkinson’s disease. Antioxidants (Basel, Switzerland) 10:121. https://doi.org/10.3390/antiox10010121
Risiglione P, Zinghirino F, Di Rosa MC, Magrì A, Messina A (2021) Alpha-synuclein and mitochondrial dysfunction in parkinson’s disease: the emerging role of vdac. Biomolecules 11. https://doi.org/10.3390/biom11050718
Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 64(6):246–254. https://doi.org/10.1038/sj.tpj.6500369
Rodolfo C, Campello S, Cecconi F (2018) Mitophagy in neurodegenerative diseases. Neurochem Int 117:156–166. https://doi.org/10.1016/j.neuint.2017.08.004
Rotermund C, Machetanz G, Fitzgerald JC (2018) The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol (Lausanne) 9:400. https://doi.org/10.3389/FENDO.2018.00400/XML/NLM
Rui YN, Xu Z, Patel B, Cuervo AM, Zhang S (2015) HTT/Huntingtin in selective autophagy and Huntington disease: a foe or a friend within? Trends Neurosci 11:858–860. https://doi.org/10.1080/15548627.2015.1039219
Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F (2012) New pharmacological strategies for treatment of Alzheimer’s disease: focus on disease modifying drugs. Br J Clin Pharmacol 73:504–517. https://doi.org/10.1111/j.1365-2125.2011.04134.x
Sandhir R, Mehrotra A (2013) Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington’s disease. Biochim Biophys Acta - Mol Basis Dis 1832:421–430. https://doi.org/10.1016/j.bbadis.2012.11.018
Scarpulla RC (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 1813:1269–1278. https://doi.org/10.1016/j.bbamcr.2010.09.019
Schmidt MY, Chamoli M, Lithgow GJ, Andersen JK (2021) Swimming exercise reduces native ⍺-synuclein protein species in a transgenic C. elegans model of Parkinson’s disease. microPublication Biol. https://doi.org/10.17912/MICROPUB.BIOLOGY.000413
Scholpa NE, Lynn MK, Corum D, Boger HA, Schnellmann RG (2018) 5-HT1F receptor-mediated mitochondrial biogenesis for the treatment of Parkinson’s disease. Br J Pharmacol 175:348–358. https://doi.org/10.1111/BPH.14076
Scott I, Youle RJ (2010) Mitochondrial fission and fusion. Essays Biochem 47:85–98. https://doi.org/10.1042/BSE0470085/78199
Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, DePinho RA, Montminy M, Cantley LC (2005) Medicine: the kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (80-. ) 310:1642–1646. https://doi.org/10.1126/science.1120781
Sheng B, Wang X, Su B, Lee HG, Casadesus G, Perry G, Zhu X (2012) Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem 120:419–429. https://doi.org/10.1111/J.1471-4159.2011.07581.X
Sheng Z-H, Cai Q (2012) Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat Rev Neurosci 13:77–93. https://doi.org/10.1038/nrn3156
Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM (2011) PARIS (ZNF746) Repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease. Cell 144:689–702. https://doi.org/10.1016/J.CELL.2011.02.010
Simmons EC, Scholpa NE, Schnellmann RG (2020) Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases. Exp. Neurol. 329:113309. https://doi.org/10.1016/J.EXPNEUROL.2020.113309
Simon DK, Lin MT, Zheng L, Liu G-J, Ahn CH, Kim LM, Mauck WM, Twu F, Beal MF, Johns DR (2004) Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson’s disease. Neurobiol Aging 25:71–81. https://doi.org/10.1016/S0197-4580(03)00037-X
Singh A, Faccenda D, Campanella M (2021) Pharmacological advances in mitochondrial therapy. EBioMedicine 65:103244. https://doi.org/10.1016/j.ebiom.2021.103244
Sleigh JN, Rossor AM, Fellows AD, Tosolini AP, Schiavo G (2019) Axonal transport and neurological disease. Nat Rev Neurol 1512(15):691–703. https://doi.org/10.1038/s41582-019-0257-2
Smith MA, Harris PLR, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94:9866–9868. https://doi.org/10.1073/pnas.94.18.9866
Suen DF, Norris KL, Youle RJ (2008) Mitochondrial dynamics and apoptosis. Genes Dev. https://doi.org/10.1101/gad.1658508
Suliman HB, Piantadosi CA (2015) Mitochondrial quality control as a therapeutic target. Pharmacol Rev 68:20–48. https://doi.org/10.1124/pr.115.011502
Szeto HH (2008) Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci 1147:112–121. https://doi.org/10.1196/ANNALS.1427.013
Szeto HH (2006) Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 82(8):E277–E283. https://doi.org/10.1007/BF02854898
Takeuchi H, Kobayashi Y, Ishigaki S, Doyu M, Sobue G (2016) Mitochondrial localization of mutant superoxide dismutase 1 triggers caspase-dependent cell death in a cellular model of familial amyotrophic lateral sclerosis. J Biol Chem 291:22341. https://doi.org/10.1074/JBC.A116.209356
Taylor RW, Turnbull DM (2005) Mitochondrial DNA mutations in human disease. Nat Rev Genet 6:389–402. https://doi.org/10.1038/nrg1606
Tefera TW, Bartlett K, Tran SS, Hodson MP, Borges K (2019) Impaired pentose phosphate pathway in the spinal cord of the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Mol Neurobiol 568(56):5844–5855. https://doi.org/10.1007/S12035-019-1485-6
Tiwari P, Wankhede N, Badole S, Umare M, Taksande B, Upaganlawar A, Umekar M, Kale M, Umekar M, Upaganlawar A, Umekar M, Kale M (2021) Mitochondrial dysfunction in ageing: involvement of oxidative stress and role of melatonin. researchgate. Net 10:156–172
Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang L-C, Boileau I, Guttman M, Hornykiewicz O, Kish SJ (2017) Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain 140:2460–2474. https://doi.org/10.1093/brain/awx172
Trivedi R (2021) Neuropsychiatric disorders: a pharmacovigilance perspective
Trushina E, Trushin S, Hasan MF (2022) Mitochondrial complex I as a therapeutic target for Alzheimer’s disease. Acta Pharm Sin B 12:483–495. https://doi.org/10.1016/J.APSB.2021.11.003
Tsujimoto Y (1998) Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 3:697–707. https://doi.org/10.1046/j.1365-2443.1998.00223.x
Tufekci KU, Civi Bayin E, Genc S, Genc K (2011) The Nrf2/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson’s disease. Parkinsons Dis. https://doi.org/10.4061/2011/314082
Twig G, Hyde B, Shirihai OS (2008) Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta - Bioenerg 1777:1092–1097. https://doi.org/10.1016/J.BBABIO.2008.05.001
Uddin MS, Al Mamun A, Kabir MT, Ahmad J, Jeandet P, Sarwar MS, Ashraf GM, Aleya L (2020) Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration. Eur J Pharmacol 886:173412. https://doi.org/10.1016/J.EJPHAR.2020.173412
Umare MD, Wankhede NL, Bajaj KK, Trivedi RV, Taksande BG, Umekar MJ, Mahore JG, Kale MB (2022) Interweaving of reactive oxygen species and major neurological and psychiatric disorders. Ann Pharm Françaises 80:409–425
Umare MD, Wankhede NL, Bajaj KK, Trivedi RV, Taksande BG, Umekar MJ, Mahore JG, Kale MB (2021) Interweaving of reactive oxygen species and major neurological and psychiatric disorders. Ann Pharm Françaises. https://doi.org/10.1016/j.pharma.2021.11.004
Upaganlawar A, Upasani C, Kale MB (2022) Medicinal potential of fenugreek in neuropathy and neuroinflammation associated disorders. Fenugreek 211–229. https://doi.org/10.1201/9781003082767-19
Upaganlawar AB, Wankhede NL, Kale MB, Umare MD, Sehgal A, Singh S, Bhatia S, Al-Harrasi A, Najda A, Nurzyńska-Wierdak R, Bungau S, Behl T (2021) Interweaving epilepsy and neurodegeneration: Vitamin E as a treatment approach. Biomed Pharmacother 143:112146
Valdés P, Mercado G, Vidal RL, Molina C, Parsons G, Court FA, Martinez A, Galleguillos D, Armentano D, Schneider BL, Hetz C (2014) Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proc Natl Acad Sci USA 111:6804–6809. https://doi.org/10.1073/PNAS.1321845111/SUPPL_FILE/PNAS.201321845SI.PDF
Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. https://doi.org/10.1016/j.biocel.2006.07.001
Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P (2010) AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 285:9100–9113. https://doi.org/10.1074/JBC.M109.060061
Vringer E, Tait SWG (2019) Mitochondria and inflammation: Cell death heats up. Front Cell Dev Biol
Walker FO (2007) Huntington’s disease. Lancet 369:218–228. https://doi.org/10.1016/S0140-6736(07)60111-1
Walker OS, Ragos R, Wong MK, Adam M, Cheung A, Raha S (2020) Reactive oxygen species from mitochondria impacts trophoblast fusion and the production of endocrine hormones by syncytiotrophoblasts. PLoS One 15:e0229332. https://doi.org/10.1371/journal.pone.0229332
Wang C, Youle RJ (2009) The role of mitochondria in apoptosis*. Annu Rev Genet 43:95–118. https://doi.org/10.1146/annurev-genet-102108-134850
Wang XL, Feng ST, Wang YT, Yuan YH, Li ZP, Chen NH, Wang ZZ, Zhang Y (2022a) Mitophagy, a form of selective autophagy, plays an essential role in mitochondrial dynamics of Parkinson’s disease. Cell Mol Neurobiol 42:1321–1339. https://doi.org/10.1007/s10571-021-01039-w
Wang X. Le, Feng ST, Wang YT, Zhang NN, Guo ZY, Yan X, Yuan YH, Wang ZZ, Chen NH, Zhang Y (2022b) Mangiferin, a natural glucoxilxanthone, inhibits mitochondrial dynamin-related protein 1 and relieves aberrant mitophagic proteins in mice model of Parkinson’s disease. Phytomedicine 104:154281. https://doi.org/10.1016/J.PHYMED.2022.154281
Wang XL,Feng ST, Wang ZZ, Chen NH, Zhang Y (2021a) Role of mitophagy in mitochondrial quality control: Mechanisms and potential implications for neurodegenerative diseases. Pharmacol Res 165. https://doi.org/10.1016/J.PHRS.2021.105433
Wang XL, Feng ST, Wang ZZ, Yuan YH, Chen NH, Zhang Y (2021b) Parkin, an E3 ubiquitin ligase, plays an essential role in mitochondrial quality control in Parkinson’s disease. Cell Mol Neurobiol 41:1395–1411. https://doi.org/10.1007/S10571-020-00914-2
Wang W, Zhao F, Ma X, Perry G, Zhu X (2020) Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances. Mol Neurodegener 151(15):1–22. https://doi.org/10.1186/S13024-020-00376-6
Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, Casadesus G, Zhu X (2008) Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 105:19318–19323. https://doi.org/10.1073/PNAS.0804871105/SUPPL_FILE/0804871105SI.PDF
Wang Y, Xu E, Musich PR, Lin F (2019) Mitochondrial dysfunction in neurodegenerative diseases and the potential countermeasure. CNS Neurosci Ther 25:816–824. https://doi.org/10.1111/cns.13116
Wankhede NL, Kale MB, Upaganlawar AB, Taksande BG, Umekar MJ, Behl T, Abdellatif AAH, Bhaskaran PM, Dachani SR, Sehgal A, Singh S, Sharma N, Makeen HA, Albratty M, Dailah HG, Bhatia S, Al-Harrasi A, Bungau S (2022) Involvement of molecular chaperone in protein-misfolding brain diseases. Biomed Pharmacoth 147:112647
Warda M, Kim HK, Kim N, Ko KS, Rhee BD, Han J (2013) A matter of life, death and diseases: mitochondria from a proteomic perspective. Expert Rev Proteomics. https://doi.org/10.1586/epr.12.69
Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic Mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950–958. https://doi.org/10.1097/00019442-200511000-00005
Wei H, Liu L, Chen Q (2015) Selective removal of mitochondria via mitophagy: distinct pathways for different mitochondrial stresses. Biochim Biophys Acta - Mol Cell Res. https://doi.org/10.1016/j.bbamcr.2015.03.013
Westermann B (2012) Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta - Bioenerg 1817:1833–1838. https://doi.org/10.1016/J.BBABIO.2012.02.033
Weydt P, Soyal SM, Gellera C, Didonato S, Weidinger C, Oberkofler H, Landwehrmeyer GB, Patsch W (2009) The gene coding for PGC-1α modifies age at onset in Huntington’s Disease. Mol Neurodegener 4:1–6. https://doi.org/10.1186/1750-1326-4-3/TABLES/4
Whitaker RM, Corum D, Beeson CC, Schnellmann RG (2016) Mitochondrial biogenesis as a pharmacological target: a new approach to acute and chronic diseases. Ann Rev Pharmacol Toxicol 56:229–249. https://doi.org/10.1146/annurev-pharmtox-010715-103155
Wu Y, Chen M, Jiang J (2019) Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion 49:35–45. https://doi.org/10.1016/j.mito.2019.07.003
Xia P, An HX, Dang CX, Radpour R, Kohler C, Fokas E, Engenhart-Cabillic R, Holzgreve W, Zhong XY (2009) Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer. https://doi.org/10.1186/1471-2407-9-454
Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, Ghoorah D, Kong X, Lin Z, Wang T (2012) Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson’s disease models. Crit Rev Toxicol 2:613–632. https://doi.org/10.3109/10408444.2012.680431
Yan X, Wang B, Hu Y, Wang S, Zhang X (2020) Abnormal mitochondrial quality control in neurodegenerative diseases. Front Cell Neurosci 14:138. https://doi.org/10.3389/FNCEL.2020.00138/XML/NLM
Yang D, Ying J, Wang X, Zhao T, Yoon S, Fang Y, Zheng Q, Liu X, Yu W, Hua F (2021) Mitochondrial dynamics: a key role in neurodegeneration and a potential target for neurodegenerative disease. Front Neurosci 15:359. https://doi.org/10.3389/FNINS.2021.654785/XML/NLM
Yang S, Xia C, Li S, Du L, Zhang L, Hu Y (2014) Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model. Cell Death Dis 55(5):e1217–e1217. https://doi.org/10.1038/cddis.2014.184
Yap LP, Garcia JV, Han D, Cadenas E (2009) The energy–redox axis in aging and age-related neurodegeneration. Adv Drug Deliv Rev 61:1283–1298. https://doi.org/10.1016/J.ADDR.2009.07.015
Youle RJ, van der Bliek AM (2012a) Mitochondrial fission, fusion, and stress. Science 337:1062–1065. https://doi.org/10.1126/science.1219855
Youle RJ, Van Der Bliek AM (2012b) Mitochondrial fission, fusion, and stress. Science (80-. ) 337:1062–1065. https://doi.org/10.1126/SCIENCE.1219855
Zambon F, Cherubini M, Fernandes HJR, Lang C, Ryan BJ, Volpato V, Bengoa-Vergniory N, Vingill S, Attar M, Booth HDE, Haenseler W, Vowles J, Bowden R, Webber C, Cowley SA, Wade-Martins R (2019) Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson’s iPSC-derived dopamine neurons. Hum Mol Genet 28:2001–2013. https://doi.org/10.1093/HMG/DDZ038
Zangari J, Petrelli F, Maillot B, Martinou J-C (2020) The multifaceted pyruvate metabolism: role of the mitochondrial pyruvate carrier. Biomolecules 10:1068. https://doi.org/10.3390/biom10071068
Zhang Z, Liu L, Wu S, Xing D (2016) Drp1, Mff, Fis1, and MiD51 are coordinated to mediate mitochondrial fission during UV irradiation-induced apoptosis. FASEB J • Res Commun. https://doi.org/10.1096/fj.15-274258
Zhao J, Liu T, Jin S, Wang X, Qu M, Uhlén P, Tomilin N, Shupliakov O, Lendahl U, Nistér M (2011) Human MIEF1 recruits Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than fission. EMBO J 30:2762–2778. https://doi.org/10.1038/EMBOJ.2011.198
Zheng J, Winderickx J, Franssens V, Liu B (2018a) A mitochondria-associated oxidative stress perspective on Huntington’s disease. Front Mol Neurosci 11:329. https://doi.org/10.3389/FNMOL.2018.00329/XML/NLM
Zheng J, Winderickx J, Franssens V, Liu B (2018b) A mitochondria-associated oxidative stress perspective on Huntington’s disease. Front Mol Neurosci
Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94:909–950. https://doi.org/10.1152/physrev.00026.2013
Author information
Authors and Affiliations
Contributions
SVM, NLW, MBK, and TB: conceived the idea and wrote the article; ABU, BGT, and MJU: figure work; MKA and HGD: literature search; SM and TB: proof read.
Corresponding author
Ethics declarations
Ethics Approval
Not applicable.
Consent for Publication
All the authors have approved the current manuscript for final publication.
Conflicts of Interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Mangrulkar, S.V., Wankhede, N.L., Kale, M.B. et al. Mitochondrial Dysfunction as a Signaling Target for Therapeutic Intervention in Major Neurodegenerative Disease. Neurotox Res 41, 708–729 (2023). https://doi.org/10.1007/s12640-023-00647-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-023-00647-2